ArticleNeurochemical research2026
Effect of 6-Hydroxydopamine on Iron Metabolism in MO3.13 Oligodendrocytes.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Iron accumulation in the substantia nigra is a hallmark of Parkinson's disease (PD), but its cellular drivers remain unclear. Oligodendrocytes, the most iron-rich cells in the brain, have been implicated in PD pathology. Our previous studies showed that 6-hydroxydopamine (6-OHDA) promotes iron accumulation in neurons and astrocytes by increasing iron influx and decreasing efflux. However, its effects on oligodendrocyte iron metabolism remain unknown. In this study, we examined how 6-OHDA affects iron homeostasis and inflammatory gene expression in MO3.13 oligodendrocytes. Using MTT, calcein-AM fluorescence assays, RT-PCR, and Western blotting, we compared undifferentiated and differentiated cells. In undifferentiated oligodendrocytes, 6-OHDA increased transferrin receptor 1 (TfR1) and iron regulatory protein 1 (IRP1) while reducing ferroportin 1 (FPN1), resulting in enhanced iron uptake and reduced export. In contrast, differentiated cells showed decreased TfR1 and IRP1 and increased FPN1, promoting iron efflux. 6-OHDA also induced stage-specific inflammatory responses. In undifferentiated cells, IL-1β and TNF-α mRNA levels rose in a dose-dependent manner, whereas differentiated cells selectively upregulated IL-1β. These results suggest that undifferentiated oligodendrocytes undergo iron-related inflammation that may promote differentiation, while differentiated cells respond with a more restricted cytokine profile. This study is the first to demonstrate that 6-OHDA promotes iron accumulation in undifferentiated oligodendrocytes by disrupting the IRP1-mediated balance between TfR1 and FPN1. Moreover, 6-OHDA induces distinct inflammatory responses depending on the stage of oligodendrocyte differentiation. These findings highlight the dual role of oligodendrocytes as both iron reservoirs and modulators of the neuroinflammatory microenvironment, providing new insights into the cellular mechanisms underlying nigral iron accumulation in PD, and suggesting that oligodendrocytes play a critical regulatory role in PD pathogenesis.
Indexed as
Identifiers
41721865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.